ArticleScience translational medicine2025

A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.

Veronica Rendo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.